<DOC>
	<DOC>NCT00835978</DOC>
	<brief_summary>Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.</brief_summary>
	<brief_title>Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>metastatic renal cell carcinoma (kidney cancer) with clear cell component no prior systemic therapy (including no prior adjuvant or neoadjuvant) Eastern Cooperative Oncology Group (ECOG) Performance Status 01 Blood Pressure &lt; or = 140/90mmHg brain/CNS metastasis using more than 2 blood pressure medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>axitinib or AG-013736 dose titration (increase) renal cell carcinoma</keyword>
	<keyword>kidney cancer</keyword>
</DOC>